A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Sophie would make a world record for being the first man or woman with cystic fibrosis to row across the Atlantic, while at ...

Glox Therapeutics secures £500K from a £3M fund to develop antibiotics targeting antimicrobial-resistant lung infections in ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Children whose cystic fibrosis is caused by a rare gene variant are excluded from a new treatment which could potentially ...

‘I feel 21 again’ – former ‘Dancing with the Stars’ judge Julian Benson on new lease of life after kidney transplant Cystic ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

K grant to accelerate development of Glox Therapeutics' novel precision antibiotics targeting AMR lung infections in people ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...